CM: TB Treatment

Target Audience

• Medical College Faculty
• Medical Students

• CM: General Concepts in TB Treatment

  • Strategies for TB Treatment
  • Pharmacological Basis of treatment
  • Treatment Phases
  • Fixed Dose Combinations [FDC]s
  • Advantages of FDCs
  • FDCs used in NTEP
  • First line anti TB drugs
  • Second Line anti TB drugs
  • Types of Drug Resistance Tuberculosis -DRTB
  • TB Drug Regimen
  • DR-TB Treatment Regimens
  • TB Treatment Initiation
  • Pre-treatment Evaluation of TB patients
  • Follow-up of TB patient
  • Follow-up sputum examination
  • TB Treatment Outcome
  • Long Term Post-treatment follow up of TB patients
  • Active TB Drug Safety Monitoring [aDSM]
  • Transfer of TB Patient Ownership

• CM: DS-TB Treatment and Care

  • Drug-Sensitive Tuberculosis [DS-TB]
  • TB Treatment – Steps
  • Treatment Regimen for DSTB – Adult
  • Treatment Regimen for DSTB - Pediatrics
  • ADRs to First Line Treatment
  • Follow-up of TB patient
  • Follow-up sputum examination
  • TB Treatment Outcome

• CM: Overview of DR-TB Treatment and care

  • DR-TB Centres and Network
  • DR-TB Treatment Regimens
  • ADRs to Second Line Treatment
  • Manage TB India Application
  • Pre-treatment Counselling
  • Pre treatment evaluation of DRTB cases
  • Interim Treatment Outcomes of DR-TB Cases
  • Final Treatment Outcomes of DR-TB Cases
  • Follow-up Monitoring of DR-TB Patients
  • Follow up sputum examination for DR-TB

• CM: Isoniazid [H] Mono/Poly DR-TB Regimen

  • Isoniazid [H] Mono/Poly DR-TB Regimen: Pre-treatment Evaluation
  • EVIDENCE FOR ISONIAZID[H] MONO/POLY DR-TB REGIMEN
  • Eligibility Criteria for H Mono/poly DR-TB Regimen
  • Eligibility Criteria for H Mono/poly DR-TB Regimen
  • Replacement Sequence in the H Mono/Poly DR-TB
  • Follow up sputum examination for Isoniazid [H] Mono/Poly DR-TB Regimen

• CM: Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen

  • Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Pre-treatment Evaluation [PTE]
  • Shorter oral Bedaquiline-containing MDR/RR-TB regimen: Evidence
  • Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment​
  • Shorter oral Bedaquiline-containing MDR/RR-TB regimen
  • Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Eligibility Criteria
  • Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Drug Dose Administration
  • Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Dosage of Drugs for Adults
  • Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen: Replacement Sequence of Drugs
  • Follow up sputum examination for Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
  • List of Drugs that can be Used Safely or Avoided along with Bedaquiline

• CM: Longer Oral M/XDR-TB Regimen

  • Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen
  • Eligibility Criteria for Longer Oral M/XDR-TB Regimen
  • Longer Oral M/XDR-TB: Regimen and Duration
  • Treatment Extension in Longer Oral M/XDR-TB Regimen
  • Dosages of M/XDR-TB Drugs for Adult in Longer Oral M/XDR-TB Regimen​
  • Details of Replacement Sequence of Drugs in Longer Oral M/XDR-TB Regimen
  • Follow up sputum examination for Longer Oral M/XDR-TB DR-TB Regimen

• CM: Treatment Support

  • Treatment Support Mechanism
  • Treatment Support Plan
  • Patient-Provider Meetings
  • Treatment supporter [TS] to TB Patient
  • Assigning a TS
  • Treatment Support Groups
  • Teleconsultation for treatment support

• CM: Adherence Management

  • TB Treatment Adherence
  • Importance of Treatment adherence
  • Recording and Monitoring Adherence
  • Digital Adherence Monitoring Technologies
  • Directly Observed Treatment [DOT]
  • Recording Adherence in Treatment card
  • Recording Adherence using TB Arogya Sathi Application
  • 99 DOTS- Features and Benefits
  • 99 DOTS- Envelopes
  • 99 DOTS- Envelope Dispensing Process
  • 99 DOTS- Initiating adherence monitoring of the patient
  • 99 DOTS- Self Reporting Adherence
  • Medication Event Reminder Monitor [MERM] Boxes
  • MERM Patient Register
  • Monitoring of Adherence by NTEP Staff
  • Adherence Summary Dashboard
  • Management of Patients with Treatment Interruptions
  • Adherence Register

• CM: ADRs to ATT

  • Adverse Drug Reactions [ADRs]
  • Types of ADR of TB Treatment
  • Management of Adverse Drug Reactions [ADRs] of TB Treatment
  • Active TB Drug Safety Monitoring [aDSM]
  • Pharmacovigilance in NTEP
  • Possible Adverse Events Due to Drugs in Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen
  • Adverse Drug Reactions due to Longer oral M/XDR-TB Regimen
  • Adverse Drug Events: H Mono/Poly DR-TB Regimen
  • ADRs to Second Line Treatment
  • Management of ADR: Rash, Allergy and Anaphylaxis Reaction
  • Management of DR-TB ADR: Gastritis, abdominal pain
  • Management of DR-TB ADR: Diarrhoea and/or Flatulence
  • Management of DR-TB ADR: Hepatitis
  • Management of DR-TB ADR: Giddiness
  • Management of DR-TB ADR: QT Prolongation
  • Management of DR-TB ADR: Hematological Abnormalities
  • Management of DR-TB ADR: Hypothyroidism
  • Management of DR-TB ADR: Arthralgia
  • Management of DR-TB ADR: Peripheral Neuropathy
  • Management of DR-TB ADR: Psychotic Symptoms
  • Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity]
  • Management of DR-TB ADR: Vestibular Toxicity

• CM: Monitoring of Treatment

  • Monitoring indicator for TB Treatment outcome
  • Monitoring indicators related to DR-TB Treatment
  • NTEP Performance Indicator - Treatment Success Rate
  • NTEP Performance Indicator – Percentage Of Multidrug-resistant [MDR]/ Rifampicin-resistant [RR] Patients Initiated on Treatment Out of Totally Diagnosed
  • RCA for low performance in in Percentage Treatment initiation of RR/MDR-TB Cases
  • DR-TB Treatment Register
  • Follow-Up Register
  • DRTB Follow Up Register